about
Hip protectors for preventing hip fractures in older peoplePersonalised risk communication for informed decision making about taking screening testsHip protectors for preventing hip fractures in older peopleCOPD and osteoporosis: links, risks, and treatment challengesPrevention and treatment of bone fragility in cancer patientOnline risk engines and scoring tools in endocrinologyTreatment of primary osteoporosis in menOsteoporosis Associated with Chronic Obstructive Pulmonary DiseaseMultimorbidity in rheumatic conditionsRecognizing and treating secondary osteoporosisFractures in indigenous compared to non-indigenous populations: A systematic review of rates and aetiologyOsteoporosis imaging: state of the art and advanced imaging.Associations between adverse social position and bone mineral density in women aged 50 years or older: data from the Manitoba Bone Density Program.Is there an interaction between socioeconomic status and FRAX 10-year fracture probability determined with and without bone density measures? Data from the Geelong Osteoporosis Study of female cohort.Correlation between osteoporotic fracture risk in Brazilian postmenopausal women calculated using the FRAX with and without the inclusion of bone densitometry data.Persistent mucosal damage and risk of fracture in celiac disease.The assessment of fracture risk.The Effect of FRAX on the Prediction of Osteoporotic Fractures in Urban Middle-aged and Elderly Healthy Chinese AdultsRace/ethnic differences in associations between bone mineral density and fracture history in older men.Association between low-frequency ultrasound and hip fractures -- comparison with DXA-based BMD.Are we taking full advantage of the growing number of pharmacological treatment options for osteoporosis?Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of prospective cohort study.Osteoporosis, fractures, and diabetes.Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis?Assessment of individual fracture risk: FRAX and beyond.The risk of osteoporotic fractures according to the FRAX model in Korean patients with rheumatoid arthritis.The utility and limitations of FRAX: A US perspective.Recent advances in managing osteoporosis.Osteoporosis and gastrointestinal disease.Bazedoxifene: literature data and clinical evidenceDetermination of an applicable FRAX model in Korean womenThe risk of osteoporotic fractures and its associating risk factors according to the FRAX model in the Iranian patients: a follow-up cohort.Cell-tethered ligands modulate bone remodeling by osteoblasts and osteoclasts.Bone health comparison in seven Asian countries using calcaneal ultrasoundBone health in patients with multiple sclerosis.Prediction of local ultimate strain and toughness of trabecular bone tissue by Raman material composition analysis.Comparison of FRAX Scores of Southern California Females of Mexican Descent Using US Hispanic and Mexico Database.Osteoporosis in chronic obstructive pulmonary diseasePrediction of incident hip fracture with the estimated femoral strength by finite element analysis of DXA Scans in the study of osteoporotic fractures.Recommendations for evaluation and management of bone disease in HIV.
P2860
Q24197773-762D5B14-4609-4BBE-BEA3-2EABECEEFEB6Q24200761-ED2C4703-8FD7-4442-9011-8E3D60078BA2Q24234655-CB49F899-0F5E-4DA4-BC79-59C51034CE4FQ26751371-0CF3196E-6438-4E26-8B49-0720B6F4A5EDQ26775765-B1D4ED1C-DA08-4FB0-9475-052A5109C90FQ26830830-BD29B804-0A21-4D7A-A62A-959603C2BCCAQ26991748-9A79B7DD-4353-453F-935D-E3618022B122Q28070018-2B7D24CF-744F-4384-B62C-723FE76569F9Q28070338-FF76977F-AFFD-4D42-AB8C-050F9E01E946Q28270738-457A1707-F2EF-4082-8E86-93EEC6F56BFDQ30234312-CC8B2623-CA04-4B24-BF1E-68831A87CEBDQ30455960-4E1A3BCC-BEF3-4938-88B3-6DE3DBB9BC73Q30592341-EA53E2C9-2E7D-47BC-A157-24EBC7C1F224Q30884007-9DB420A6-DDF2-4369-95C0-EDF0F694FB8FQ31074076-BC7FCCA0-2B82-4551-A455-07B16CD97AABQ33570033-C88BCA59-A716-4ECA-885C-79C1982EDC16Q33685092-8ACC8D66-4136-4BC4-BA2B-E2E65C717558Q33711311-FFC1C4C6-BEA1-4A66-A641-4D7C6F123A3FQ33760194-53F2667A-3794-4B6E-960B-19C4C881255EQ33794425-13E936C1-C9E3-47D8-84C6-960D2426ECEAQ33811677-E27C4D8A-9215-4BED-96D9-1C1AE33713BAQ33842226-DB1FC2DA-0CDA-463E-A4A2-46F1F99C68B7Q33891378-AF7159E2-87F2-426A-A632-B9FE6472924CQ33912916-68EBF4F1-2914-4465-84FA-8A07A1EAA660Q33988058-A834F59B-A027-4088-88B4-E0BF78B466CBQ34029944-5B1F63D4-5B52-4C66-847C-D8F39DD61166Q34161186-6D05DDFB-7484-424E-9A5C-F535347958CEQ34167436-111C1177-2E71-4C23-9EAD-B6CE0408E516Q34178759-F2D1CFE1-D6E4-459A-9D4D-3E41137D1A91Q34213748-667320C7-9815-42BA-8602-33CAEDDC038CQ34255661-FC1F7887-3ACB-46D6-97D0-EDA0FAD2830CQ34402171-D3AE8E1A-3FE5-403C-B98D-3375A06C3DD0Q34534946-EAABCD01-F14E-4471-BC5B-6FFE0AF8D91BQ34622715-C21726C8-BF9D-4B52-AF68-19C13D30BD99Q34986532-E927C814-F84E-4241-B6A8-E1D20888E301Q35071764-659F385F-976C-46CD-99B3-9FF664449461Q35101702-242E1A1D-7FE8-4DFD-9CD4-7D1F7D148C13Q35173349-9E3CB53F-1AF6-4F0E-BFC1-B9AC3D377277Q35299652-9A89107F-B815-4BA9-851C-DC59A31687D2Q35451868-4E58D25D-FFC4-4295-A148-948BA79C447B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
FRAX and its applications to clinical practice.
@en
FRAX and its applications to clinical practice.
@nl
type
label
FRAX and its applications to clinical practice.
@en
FRAX and its applications to clinical practice.
@nl
prefLabel
FRAX and its applications to clinical practice.
@en
FRAX and its applications to clinical practice.
@nl
P2093
P1433
P1476
FRAX and its applications to clinical practice.
@en
P2093
Anders Oden
Eugene McCloskey
Fredrik Borgström
Helena Johansson
John A Kanis
Oskar Ström
P304
P356
10.1016/J.BONE.2009.01.373
P577
2009-02-03T00:00:00Z